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Abstract: In our community Diabetes Mellitus and pulmonary Tuberculosis are still very common. The % of Pulmonary Tuberculosis among diabetic patients is nearly 27% by radiological diagnosis (377J IMA vol 100NO.6 june 2002). The % of diabetes among pulmonary tuberculosis patients is 6.5%. Both diseases are chronic and co-exist not commonly. It is said that if tuberculosis is uncontrolled inspite of meticulous anti TB treatment of tuberculosis patients suspect latent diabetes. When both diseases coexist they are mutually aggravating. If they are simultaneously treated effectively the effect is good. Unfortunately TB requires polypharmacy. Some of the recent anti TB drugs like Rifampicin have enzyme inducing capacity producing a low blood level concentration of certain drugs like glibenclamide ( sulphonylurea) with which it interacts. In maturity onset diabetic (NIDDM)patients with TB taking glibenclamide for the control of diabetes and

I. Review of Literature:
Prevalence of Diabetes -The Global Senario. The WHO estimated that there are 135 million diabetic individuals in the year 1995 and it has projected that this number would increase to 300 million by the year 2025
2
. It also declared that Diabetes had reached epidemic proportions and predicts that most of the increase will be contributed by developing countries, particularly India 3 . Prevalence of Diabetes -The Indian scenario. India today leads the world with its largest number of diabetic subjects in any give country 3,4. It has been estimated that presently 19.4 million individuals are affected by diabetes and these numbers are expected to increase to 57.2 million by the year 2025 2 .
(1/6 of the world total).The diabetic classification was adopted in 1980, and modified in 1985 5, 6 . In 1970's the prevalence of diabetes among urban Indians was reported to be 2.1%, this has now risen to 12.1% 7, 8 . Induction of Rifampicin metabolism during treatment in TB patients with daily and fully intermittent regimens containing the drug 9,10,11,12 .Self induction of Rifampicin metabolism during daily and intermittent cheamotherapy was studied by monitoring the changes in the serum half life of the drug over a week period in patients with PT. Rifampicin 450 mg was administered to 8 patients who received treatment daily, to 7 patients taking thrice weekly and 8 others on twice weekly treatment 13 . Serum half life was computed from concentrations of the drug determined at 3, 4½, and 6 hours after drug administration, on admission and at 1,2 and 4 weeks after starting of treatment. In the daily series, the mean serum half life decreased from 4.9 hours on admission to 3.6 hours at 1week (P=0.02), and treatment beyond this had no further effect 14 
.
In the thrice weekly series, maximal induction was observed at the 2 nd week, the main values on admission and at 2weeks being 5.8 and 3.7 hours respectively. (P=0.01). In the twice weekly series maximal induction was observed only at the 4 th week, the mean values on admission and at 4weeks being 4.9 and 3.7 hours respectively
15
.
Rifampicin:
This appears to stimulate the metabolism of glibenclamide by hepatic microsomal enzymes. It shown to enhance considerably the disposition of glibenclamide and decreases half life and impairs hypoglycaemic response. When Rifampicin and Glibenclamide are used concomitantly one should be alert for diminished hypoglycaemic activity of Glibenclamide.
II. Aims and Objectives:
Detection of drug interaction between anti tubercular Rifampicin and oral antidiabetic Glybenclamide by Pharmacokinetic study of diabetic state. Control of both diseases simultaneously by rectifying hyperglycaemic effect of Rifampicin on control of diabetes. Comparing study group treated with HREZ and control group with HEZ to prove Rifampicin is the drug responsible for hyperglycaemia.
III. Materials and Methods:
Patients suffering from both Tuberculosis and Diabetes Mellitus type-II were selected betwin age groups 35 -60yrs and admitted in This Hospital.The patient should be non smoker, non alcoholic with normal liver and kidney function.
A minimum of 40 such patients were randomly distributed into two groups of 20 each. Informed consent was obtained from each subject and institutional ethics committee permission was taken. Both the groups were put on 3 drug regimen (HEZ) and glibenclamide 2.5 mg Bid and the fasting glucose levels were normalized by about 5 th day. Then in the study group Rifampicin 600mg to patients above 50kg and 450mg to patients below 50kg was added to the above regimen. In the control group 3drug regimen (HEZ)+ glibenclamide continued. Fasting blood glucose levels were estimated on alternate days in both the groups . The day at which the blood glucose levels increased was noted in the study group. It indicates the stage of drug interaction. After detecting the rise of blood glucose levels and there is no further increase for two days the dose of glibenclamide was increased to compensate the effect produced by drug interaction and blood glucose levels normalized in about 5days in the study group.In the control group there is no significant increase in fasting glucose levels and the same dose of glibenclamide continued. Unpaired 't' test was used for the statistical analysis.
IV. Results
Total 40 cases of confirmed pulmonary Tuberculosis and Type II Diabetes Mellitus, who were non smokers and non alcoholics and whose diabetes is of less than 5 years duration and whose blood sugar is under control with less than 40 units of Insulin per day were selected in this study.These cases were divided into two groups of 20 each, study group and control group and studied and analyzed for pharmacological detection of drug interaction. (Table-1-control group and Table-2 
-study group).
Tables: Table - 1  156642  38  Male  55  176  106  100  104   HEZ+  glibenclamid  e  2  113942  42  Female  54  167  98  102  96  "  3  117819  44  Male  61  180  110  106  108  "  4  114944  46  Female  56  174  90  96  94  "  5  182418  51  Male  59  186  96  90  98  "  6  117889  54  Female  55  166  106  101  108  "  7  132526  37  Male  60  160  88  92  94  "  8  132211  52  Male  62  186  112  98  104  "  9  117427  44  Female  56  209  86  90  88  "  10  115581  41  Male  58  168  110  102  106  " 11  205531  38  Female  52  146  82  90  86  "  12  182490  55  Male  60  182  114  108  110  "  13  205702  46  Female  54  172  118  104  108  "  14  132967  48  Male  56  180  116  106  112  "  15  112735  35  Female  51  192  90  96  96  "  16  133424  53  Male  58  188  114  104  116  "  17  155797  49  Female  51  162  92  98  94  "  18  140587  46  Male  58  190  108  102  110  "  19  160742  55  Female  51  168  88  92  96  "  20  183473  40  Male  54  172  104  110 Female  48  178  114  145  110  "  7  121178  38  Male  60  149  96  141  102  "  8  146637  54  Male  58  186  116  120  120  "  9  157680  55  Female  51  148  90  131  94  "  10  117204  40  Male  56  164  115  145  110  "  11  141194  46  Male  53  180  110  135  108  "  12  123463  44  Female  48  181  104  142  111  "  13  183120  39  Male  54  154  98  136  105  "  14  116649  55  Female  47  158  95  132  102  "  15  156121  48  Male  61  186  111  146  116  "  16  146605  56  Female  60  172  98  136  106  "  17  157680  38  Male  57  188  116  130  114  "  18  145493  52  Female  56  141  80  126  92  "  19  144274  52  Male  62  190  112  138  114  "  20  159241  46  Female  54  148  96  131  100  "  Mean  167  103  136  107  SD ± 16.02 ± 10.15 ± 7.14 ± 7.36 *R = Rifampicin added on 5th day *G = Increased dose of glibencalmide on 15th day
V. Discussion
In both groups fasting blood glucose levels were taken initially and both the groups were put on Anti TB drugs H.E.Z. and glibenclamide and the Fasting blood glucose levels were normalized by about 5 th day . After the normal levels have reached Rifampicin was added according to body weight in the study group. In the study group the fasting blood glucose levels were raised gradually and reaches maximum by 8 th day of addition of Rifampicin from 103 mg/dl to 136mg/dl. The blood sugar value was significantly raised. In the control group there is no such rise in fasting blood glucose as found in study group. The blood sugar levels on 5 th day is 101mg/dl and on 15 th day is 102mg/dl. There is no significant difference. Comparision of raised blood glucose levels in study group and control group, There is a significant difference (P=<0.05) in both groups on 15th day of treatment i.e. 10 th day of start of Rifampicin therapy. The blood glucose levels were gradually increased from 5 th day and reaches maximum by 8 th day of starting of Rifampicin therapy in study group and later remained constant. From 10 th day the dose of glibenclamide was increased to reduce the blood glucose levels to normal.
VI.
Summary:
This work is done to show the drug interaction. When so many drugs are used, the effect of one drug may inhibit the action or potency of other drugs and there by decreasing the chances of recovery from the disease. In this study we have simultaneously treated the tuberculosis with the anti TB drugs and diabetes with oral sulphonylurea. But in the study group we have added the Rifampicin which produced a diminished effect of glibenclamide due to increased metabolism by enzyme induction. So there is an increase in fasting blood glucose level, and this is controlled by increasing the dose of glibenclamide. This hyperglycaemia may prevail the existing TB and chances of recovery is less unless the blood sugar level is within normal limits. The study of drug interaction is very important and vital particularly in therapy with potent drugs because the multiple drug therapy has come to stay in the present day clinical practice in long term treatment, to avoid resistance.
INFERENCE:
In this study in patients with glibenclamide and anti TB drugs HREZ, drug interaction was detected as raised blood glucose, on 15 th day (i.e. 8 th -10 th day of Rifampicin therapy). In control group patients with glibenclamide and antiTB drugs (Non Rifampicin) HEZ there was no such drug interaction. Blood glucose levels were unchanged. After drug interaction hyperglycaemia was continued in study group and it was compensated by increased dose of glibenclamide. So in clinical practice during treating a patient having both PT and Type II diabetes mellitus , the result of the study is quiet useful to avoid hyperglycaemia.
VII.
Conclusion:
In case of TB patients with diabetes mellitus Type II if we give short course chemotherapy with Rifampicin regimen you should be cautious about drug interaction. You should increase the dose of oral hypoglycaemic sulfonylurea to control diabetes and pulmonary tuberculosis.
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